NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free IONS Stock Alerts $37.31 -0.31 (-0.82%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$36.56▼$37.6650-Day Range$37.62▼$44.6652-Week Range$35.92▼$54.44Volume1.36 million shsAverage Volume1.15 million shsMarket Capitalization$5.45 billionP/E RatioN/ADividend YieldN/APrice Target$59.54 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ionis Pharmaceuticals alerts: Email Address Ionis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside59.6% Upside$59.54 Price TargetShort InterestHealthy6.53% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.69Based on 13 Articles This WeekInsider TradingSelling Shares$422,910 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.96) to ($3.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.65 out of 5 starsMedical Sector85th out of 922 stocksPharmaceutical Preparations Industry27th out of 429 stocks 4.4 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 9 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.53% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 8.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 3.7 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Ionis Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest13 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat Follows5 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $422,910.00 in company stock.Percentage Held by InsidersOnly 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.96) to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 18.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. About Ionis Pharmaceuticals Stock (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesMay 8, 2024 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Sells $256,260.00 in StockApril 18, 2024 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi Sells 4,006 SharesMay 17 at 1:53 PM | markets.businessinsider.comIonis Pharmaceuticals Buy Rating Affirmed on Strong Clinical Data and Robust Pipeline PotentialMay 16 at 12:46 PM | markets.businessinsider.comIonis Reports Positive Topline Data From The HALOS Phase 1/2a Study In Angelman SyndromeMay 16 at 7:41 AM | reuters.comBiogen, Ionis to discontinue development of ALS drugMay 16 at 7:30 AM | prnewswire.comIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 16 at 7:00 AM | prnewswire.comIonis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndromeMay 15 at 7:05 AM | prnewswire.comIonis to host 2024 virtual Annual Meeting of StockholdersMay 12, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Ionis Pharmaceuticals (NASDAQ:IONS)May 10, 2024 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) PT Lowered to $82.00May 9, 2024 | finance.yahoo.comThe Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 8, 2024 | washingtonpost.comTKO Group: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comThe Analyst Landscape: 8 Takes On Ionis PharmaceuticalsMay 8, 2024 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comIonis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...May 8, 2024 | finance.yahoo.comQ1 2024 Ionis Pharmaceuticals Inc Earnings CallMay 8, 2024 | finance.yahoo.comIonis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 8, 2024 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III Sells 6,000 Shares of StockMay 7, 2024 | finanznachrichten.deIonis Pharmaceuticals, Inc.: Ionis reports first quarter 2024 financial resultsMay 7, 2024 | msn.comIONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | prnewswire.comIonis reports first quarter 2024 financial resultsMay 6, 2024 | msn.comIonis Pharmaceuticals Q1 2024 Earnings PreviewApril 25, 2024 | prnewswire.comIonis Publishes 2023 Corporate Responsibility ReportApril 23, 2024 | prnewswire.comIonis to hold first quarter 2024 financial results webcastApril 15, 2024 | nasdaq.comIONS Quantitative Stock AnalysisSee More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/17/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees927Year FoundedN/APrice Target and Rating Average Stock Price Target$59.54 High Stock Price Target$82.00 Low Stock Price Target$28.00 Potential Upside/Downside+58.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-366,290,000.00 Net Margins-49.49% Pretax Margin-46.88% Return on Equity-107.64% Return on Assets-13.17% Debt Debt-to-Equity Ratio4.15 Current Ratio7.37 Quick Ratio7.28 Sales & Book Value Annual Sales$788 million Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book18.53Miscellaneous Outstanding Shares145,960,000Free Float142,097,000Market Cap$5.49 billion OptionableOptionable Beta0.41 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 63)Founder, CEO & Director Comp: $1.71MMs. Elizabeth L. Hougen M.A. (Age 62)M.B.A., M.S., Executive VP of Finance & CFO Comp: $1.02MMs. B. Lynne Parshall Esq. (Age 70)J.D., Senior Strategic Advisor & Director Comp: $334.64kDr. Richard S. Geary Ph.D. (Age 66)Executive VP & Chief Development Officer Comp: $946.26kMr. Joseph T. Baroldi M.A. (Age 45)M.B.A., M.S., Executive VP & Chief Business Officer Comp: $815.87kMr. Darren GonzalesChief Accounting Officer & Senior VPDr. C. Frank Bennett BSc (Age 67)Ph.D., Executive VP & Chief Scientific Officer Comp: $651.64kMr. D. Wade Walke Ph.D.Senior Vice President of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 50)Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary Comp: $815.69kMs. Hayley SofferVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDBausch Health CompaniesNYSE:BHCACADIA PharmaceuticalsNASDAQ:ACADView All CompetitorsInsiders & InstitutionsZimmer Partners LPBought 270,300 shares on 5/17/2024Ownership: 0.185%Walleye Trading LLCBought 46,800 shares on 5/17/2024Ownership: 0.000%Tidal Investments LLCBought 20,405 shares on 5/17/2024Ownership: 0.014%California State Teachers Retirement SystemSold 6,714 shares on 5/16/2024Ownership: 0.090%Paloma Partners Management CoBought 4,909 shares on 5/16/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions IONS Stock Analysis - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IONS shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price target for 2024? 14 brokerages have issued twelve-month price objectives for Ionis Pharmaceuticals' stock. Their IONS share price targets range from $28.00 to $82.00. On average, they expect the company's share price to reach $59.54 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2024? Ionis Pharmaceuticals' stock was trading at $50.59 at the beginning of the year. Since then, IONS shares have decreased by 26.3% and is now trading at $37.31. View the best growth stocks for 2024 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.12. The firm had revenue of $119 million for the quarter, compared to analysts' expectations of $131.42 million. Ionis Pharmaceuticals had a negative net margin of 49.49% and a negative trailing twelve-month return on equity of 107.64%. The company's quarterly revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.87) earnings per share. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), Horizon Kinetics Medical ETF (MEDX), Invesco Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), Tema Cardiovascular and Metabolics ETF (HRTS), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $618.1 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Bellevue Group AG (5.69%), Clearbridge Investments LLC (3.06%), Price T Rowe Associates Inc. MD (2.41%), Jacobs Levy Equity Management Inc. (0.39%) and Baillie Gifford & Co. (0.20%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Baroldi, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IONS) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA ‘DeFi Summer’ Projected!Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceThe #1 Investment of the Decade… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
